Validation of the lung immune prognostic index in extensive-stage small cell lung cancer: Post hoc analysis of the caspian and IMpower133 phase 3 trials.

Eur J CancerJul 22, 2026 (epub)
Clinical ResearchOncology (Medical)

Edouard Auclin, Matthieu Roulleaux Dugage, Teresa Gorría et al.

✦ AI-curated · Sources linked

In 30 seconds

This validation study assessed the Lung Immune Prognostic Index (LIPI) in extensive-stage small cell lung cancer (ES-SCLC) using data from the CASPIAN and IMpower133 phase III trials. Among 1140 patients, median overall survival (OS) was 14.6 months for LIPI Good, 10.9 months for Intermediate, and 8.4 months for Poor (p < 0.0001), confirming LIPI's prognostic value in this population.

Key findings

  • LIPI was categorized as Good in 34%, Intermediate in 49%, and Poor in 17% of patients.
  • Median OS was 14.6 months for Good, 10.9 months for Intermediate, and 8.4 months for Poor LIPI (p < 0.0001).
  • LIPI remained an independent prognostic factor for OS with HR Poor vs. Good: 1.76 (95%CI: 1.45-2.15, p < 0.001).
  • Patients with poor LIPI derived limited benefit from immunotherapy.

Why it matters

The study underscores the importance of LIPI as a prognostic biomarker in ES-SCLC, providing clinicians with a tool to better stratify patients based on expected outcomes and tailor treatment approaches accordingly.

Source

PubMed · PMID 42520592

Published in Eur J Cancer. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.